Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00358345
Other study ID # PHP C9
Secondary ID
Status Completed
Phase Phase 4
First received July 27, 2006
Last updated January 10, 2008
Start date October 2003
Est. completion date September 2007

Study information

Verified date January 2008
Source Notal Vision Ltd
Contact n/a
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Observational

Clinical Trial Summary

The primary objective of this study is to assess the ability of the PreView PHP(study device)to detect newly diagnosed non-treated Choroidal Neovascularization (CNV)lesion associate with advanced Age-related Macular Degeneration (AMD) or Myopia and differentiate them from Intermediate AMD or Geographic Atrophy (GA)or patients with high Myopia with no CNV.

This study secondary is to enhance NotalVision normative database.


Description:

- The study is prospective, multi-center, comparative study.

- A clinical trail with FDA approval device (510K).


Recruitment information / eligibility

Status Completed
Enrollment 347
Est. completion date September 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Newly diagnosed (up yo 2 months) CNV OR Intermediate AMD

- Age >50 for AMD subjects

- Age >18 for Myopic subjects

- VA 20/160 or better in the study eye

- Mental and physical ability to performed a PHP test

Exclusion Criteria:

- Evidence of macular disease other than AMD or high myopia in the study eye.

- Previous surgical or laser treatment within the macular erea.

- Concurrent intraocular drug therapy (within 30 days).

- Present of any significant media opacity that preclude a clear veiw of the macula.

- Any non macular related ocular surgery performed within 3 months prior to the study.

- CNV subjects inability to tolerate intravenous fluorscien angiography.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Locations

Country Name City State
Israel Tel Aviv Sourasky medical center Tel Aviv

Sponsors (1)

Lead Sponsor Collaborator
Notal Vision Ltd

Country where clinical trial is conducted

Israel, 

See also
  Status Clinical Trial Phase
Recruiting NCT03963817 - Snapshot Camera for AMD
Recruiting NCT04929756 - Eye Movement Rehabilitation in Low Vision Patients
Completed NCT04779398 - Association of MPOD Values With Blue Light.
Terminated NCT03275753 - Visual Function Tests in Age-related Macular Degeneration
Recruiting NCT03609307 - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial Phase 2/Phase 3
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Active, not recruiting NCT01943396 - Treatment of AMD With Rheohemapheresis /RHF/ Phase 4
Completed NCT00963339 - Age-Related Macular Degeneration (AMD) - Usability Study N/A
Completed NCT00376701 - Combination Therapy for Age-Related Macular Degeneration. Phase 2
Terminated NCT00347165 - Intravitreal Bevacizumab for Age-Related Macular Degeneration Phase 2
Completed NCT00800995 - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD) Phase 3
Completed NCT04689789 - OCTA and Retinal Angiomatous Proliferation
Completed NCT02567604 - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed NCT02173496 - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Recruiting NCT01991730 - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients N/A
Active, not recruiting NCT01657669 - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results Phase 4
Completed NCT00776763 - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab Phase 2
Completed NCT00791570 - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy Phase 1
Completed NCT00413829 - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) Phase 2